Among the different combined hypoglycemic treatment regimens, combined therapy with GLP‐1RA and basal insulin reflected the advantages of a lower hypoglycemic risk and more weight reduction with noninferior potency of glycemic control; this enables the achievement of the ideal goal in diabetic treatment robust glycemic control with no increased hypoglycemia or weight gain.28 The gene discussed is INS; the disease is Hypoglycemia.